Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
Trial design randomized 175 symptomatic oHCM patients (NYHA II–III; LVOT gradient ≥30 mm Hg rest or ≥50 mm Hg Valsalva) to titrated aficamten 5–20 mg or metoprolol 50–200 mg for 24 weeks. Across 16 ...
In the ACACIA-HCM trial, aficamten demonstrated a statistically significant improvement over placebo in both KCCQ-CSS (P =.021) and pVO2 (P =.003) at 36 weeks, with no new safety signals observed.
Cytokinetics' cardiac myosin inhibitor Myqorzo has succeeded where first-to-market Camzyos from Bristol Myers Squibb failed, hitting the mark in a phase 3 trial in non-obstructive hypertrophic ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
These promising results-from an NIH-funded study that exclusively evaluated Masimo SET ® in a vulnerable, clinically fragile patient population-add to previously published evidence of its strong ...
Cytokinetics, Incorporated CYTK announced that the European Commission (EC) has approved Myqorzo (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets, for the treatment of adult patients with symptomatic ...
A major UK study shows that commonly used home pulse oximeters can overestimate oxygen levels in people with darker skin, increasing the risk of undetected hypoxemia and raising urgent questions about ...
Pulse oximeters that can be used at home to detect hypoxaemia give higher readings for patients with darker than lighter skin tones, according to UK researchers. As a result, they warn that low blood ...
In the EXAKT study from the U.K., the home-use pulse oximeters assessed all gave higher oxygen saturation (SpO2) readings for patients with darker skin tones than for patients with lighter skin tones.
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO® (aficamten) has been approved by the China National Medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results